11.78

9.68% +1.04

After Hours: 11.78

ITeos Therapeutics Inc (ITOS)

Overview News Price History Option Chain Discussions Forecast

ITeos Therapeutics Inc stock is currently priced at $11.78, with a 24-hour trading volume of 407.77K. It has seen a +9.68% increased in the last 24 hours and a -11.69% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $10.77 pivot point. If it approaches the $11.04 resistance level, significant changes may occur.

Previous Close:

$10.74

Open:

$10.81

24h Volume:

407.77K

Market Cap:

$423.67M

Revenue:

$127.70M

Net Income/Loss:

$-112.64M

P/E Ratio:

-14.37

EPS:

-0.82

Net Cash Flow:

$-106.72M

1W Performance:

+11.45%

1M Performance:

-11.69%

6M Performance:

+18.87%

1Y Performance:

-16.28%

1D Range:

$10.60

$11.81

52W Range:

$8.20

$18.24

ITeos Therapeutics Inc Stock (ITOS) Company Profile

Name

ITeos Therapeutics Inc

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

Address

139 Main Street, Cambridge

Employee

Twitter

Next Earnings Date

2024-05-08

Latest SEC Filings

ITOS's Discussions on Twitter

ITeos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-05-21	Initiated	H.C. Wainwright	Buy
Oct-08-20	Initiated	Robert W. Baird	Outperform
Aug-18-20	Initiated	JP Morgan	Overweight
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	SVB Leerink	Outperform
Aug-18-20	Initiated	Wedbush	Outperform

View All

ITeos Therapeutics Inc Stock (ITOS) Latest News

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

GlobeNewswire Inc.

iTeos gibt Geschäftsergebnisse für das vierte Quartal und das Gesamtjahr 2023 sowie Unternehmensneuigkeiten bekannt

GlobeNewswire Inc.

iTeos beruft erfahrene Onkologieexpertin Jill DeSimone in seinen Verwaltungsrat

GlobeNewswire Inc.

iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

GlobeNewswire Inc.

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

GlobeNewswire Inc.

iTeos nimmt an bevorstehenden Investorenkonferenzen teil

GlobeNewswire Inc.

ITeos Therapeutics Inc Stock (ITOS) Financials Data

ITeos Therapeutics Inc (ITOS) Revenue 2024

ITOS reported a revenue (TTM) of $127.70 million for the quarter ending March 31, 2023.

ITeos Therapeutics Inc (ITOS) Net Income 2024

ITOS net income (TTM) was -$112.64 million for the quarter ending December 31, 2023, a -216.54% decrease year-over-year.

ITeos Therapeutics Inc (ITOS) Cash Flow 2024

ITOS recorded a free cash flow (TTM) of -$106.72 million for the quarter ending December 31, 2023, a +4.82% increase year-over-year.

ITeos Therapeutics Inc (ITOS) Earnings per Share 2024

ITOS earnings per share (TTM) was -$3.15 for the quarter ending December 31, 2023, a -223.53% decline year-over-year.

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains. The company was founded in 2011 and is based in Cambridge, Massachusetts with an additional location in Gosselies, Belgium.